Annals of Oncology Impact Factor

The trend is striking. Annals of Oncology has more than doubled its JIF since 2020, moving from 33.1 to 65.4. Unlike most journals that peaked in 2021 and then declined, Annals of Oncology has continued climbing. This likely reflects the journal's strategic decision to publish more major clinical trial results and ESMO clinical practice guidelines, both of which generate very high citation counts.

For authors, this upward trajectory means the journal is becoming more selective, not less. The editorial bar has risen alongside the metric.

At 65.4, Annals of Oncology is now competitive with the very top medical journals on raw citation performance. For context, JAMA is at 55.0 and BMJ at 42.7. In oncology specifically, only CA: A Cancer Journal for Clinicians (232.4, which is a review/statistics journal) and a few Nature Reviews titles sit above it.

That JIF level is driven primarily by large clinical trials and guideline publications. Individual research papers in the journal may not all reach that citation level. The distribution is skewed: a few highly cited papers pull the average up significantly. Authors should use the JIF as a tier signal, not as a prediction for individual paper performance.

Annals of Oncology editors want clinical evidence that changes how oncologists manage patients. The journal's identity is guideline-adjacent and ESMO-connected, which means:

• practice-altering trial results get the most attention
• translational work needs a clear clinical consequence
• European oncology perspectives have natural editorial fit
• papers that feed into guideline discussions carry extra weight
• data quality and study design must be at the highest level

In our pre-submission review work on manuscripts targeting Annals of Oncology, three patterns account for most of the desk rejections we see.

Phase I studies submitted without substantial translational research components. Annals of Oncology's documented editorial guidelines state explicitly: "Reports of phase I studies will only be considered where there are additional translational research components." This is one of the clearest scope exclusions in high-impact oncology publishing. We see first-in-human dose-escalation trials, PK/PD studies, and safety expansion cohorts submitted to Annals of Oncology on the basis of the drug's novelty or the target's clinical importance. The editorial office returns these quickly, mean time to first decision is documented at 15 days, and desk rejections often come faster. The intervention is not to wait for phase II results before submitting; it is to ensure that pharmacodynamic biomarkers, tumor microenvironment analyses, or target engagement data are integrated into the primary manuscript as co-primary components rather than appendices. Phase I papers that pass Annals of Oncology's editorial bar are structured so that the translational findings are as central to the manuscript as the safety and dosing data.

Studies of "insufficient priority", technically sound papers that don't clear the practice-changing threshold. Annals of Oncology's documented editorial language states that papers "found to be of insufficient priority" will be returned within three weeks. The journal rejects approximately 87% of submitted manuscripts. What this means operationally is that a paper can be well-designed, accurately reported, and scientifically sound and still fail at triage because the practice consequence is not immediate enough for ESMO's clinical readership. We see papers that confirm a treatment's efficacy in a patient population where practice is already established, papers that validate a biomarker in a retrospective cohort without changing treatment selection, and papers that report correlative analyses from completed trials without a clear action implication. The distinction Annals of Oncology editors draw is between papers that an ESMO-readership oncologist would change how they treat patients after reading and papers that would confirm what they're already doing. Reframing the significance argument to lead with the specific treatment decision the findings affect (not the biological interest or the patient population) is the most direct available response to this pattern.

US-centric or single-region studies submitted without acknowledging global scope. Annals of Oncology is the ESMO flagship, and its documented editorial identity emphasizes European oncology perspectives and international applicability. We see clinical trials and retrospective analyses that enrolled exclusively or predominantly from US centers, with patient demographics, treatment protocols, and guideline references that map onto ASCO and National Comprehensive Cancer Network standards rather than ESMO ones. The issue is not that the science is wrong for a European audience; it is that the manuscript does not demonstrate awareness of how the findings would apply in European clinical contexts. Papers where the primary care standard being compared against is Medicare-adjacent, or where systemic treatment sequences follow FDA-approved regimens without acknowledging EMA-approved alternatives, often receive desk rejections or reviewer comments asking about global applicability. The practical fix for international trials is ensuring the patient population, treatment protocols, and significance framing address ESMO's geographic readership explicitly.

It does not tell you whether the clinical consequence is broad enough, whether ESMO's editorial lens favors your disease area, or whether JCO would actually give the paper better US-facing visibility. For clinical oncology submissions at this level, an Annals of Oncology clinical framing and statistics check can help pressure-test the clinical framing and statistical presentation.